- Case report
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Three siblings with familial non-medullary thyroid carcinoma: a case series
© The Author(s). 2016
Received: 4 April 2016
Accepted: 6 July 2016
Published: 2 August 2016
In 2015, thyroid carcinoma affected approximately 63,000 people in the USA, yet it remains one of the most treatable cancers. It is mainly classified into medullary and non-medullary types. Conventionally, medullary carcinoma was associated with heritability but increasing reports have now begun to associate non-medullary thyroid carcinoma with a genetic predisposition as well. It is important to identify a possible familial association in patients diagnosed with non-medullary thyroid carcinoma because these cancers behave more destructively than would otherwise be expected. Therefore, it is important to aggressively manage such patients and screening of close relatives might be justified. Our case series presents a diagnosis of familial, non-syndromic, non-medullary carcinoma of the thyroid gland in three brothers diagnosed over a span of 6 years.
We report the history, signs and symptoms, laboratory results, imaging, and histopathology of the thyroid gland of three Pakistani brothers of 58 years, 55 years, and 52 years from Sindh with non-medullary thyroid carcinoma. Only Patients 1 and 3 had active complaints of swelling and pruritus, respectively, whereas Patient 2 was asymptomatic. Patients 2 and 3 had advanced disease at presentation with lymph node metastasis. All patients underwent a total thyroidectomy with Patients 2 and 3 requiring a neck dissection as well. No previous exposure to radiation was present in any of the patients. Their mother had died from adrenal carcinoma but also had a swelling in the front of her neck which was never investigated. All patients remained stable at follow-up.
Non-medullary thyroid carcinoma is classically considered a sporadic condition. Our case report emphasizes a high index of suspicion, a detailed family history, and screening of first degree relatives when evaluating patients with non-medullary thyroid carcinoma to rule out familial cases which might behave more aggressively.
According to the American Cancer Society, in 2015 the number of people with thyroid cancer in the USA was approximately 63,000 and it caused 2000 deaths . Approximately 1.1 % of people will be diagnosed with it at some point in their life, yet it remains one of the most treatable cancers with a median 5-year survival rate of 98 % . Thyroid cancer is divided into two chief types: medullary, which arises from parafollicular C cells, and non-medullary, which arises from follicular epithelial cells. Non-medullary thyroid carcinoma (NMTC) includes papillary thyroid carcinoma, follicular thyroid carcinoma, Hürthle cell carcinoma, and anaplastic thyroid carcinoma and these make up 95 % of thyroid malignancies of which papillary carcinoma is the most common . Although medullary carcinoma is traditionally associated with a genetic predisposition and a susceptibility gene, RET, has been identified, increasing evidence is now accumulating about the heritability of NMTC as well . Familial NMTC (FNMTC) is defined as two or more first-degree relatives affected by thyroid cancer without another familial syndrome; this familial clustering has been reported in 3.5 to 10.0 % of cases [1, 3]. Heritability is usually in the form of syndromes such as familial adenomatous polyposis, Cowden syndrome, and Werner syndrome where the majority of tumors are in organs other than the thyroid. Non-syndromic FNMTC is a rare entity which most likely follows an autosomal dominant path with incomplete penetrance and variable expression .
Patient 2 is a younger brother of Patient 1; Patient 2 is a 55-year-old man from Karachi, Pakistan who underwent a thyroid ultrasound for screening purposes although he was asymptomatic. No abnormality was noted on physical examination. His ultrasound showed an enlarged right lobe as compared to the contralateral side measuring 20.2×24.3×39.5 mm. At least three hypoechoic nodules with predominant solid components were seen in his right lobe with tiny calcification present within. The largest nodule measured 20.8×17.0 mm. Ultrasound-guided FNA revealed clusters and groups of follicular cells with architectural atypia, with a few of the cells forming papillary structures. Some nuclear grooving and intranuclear inclusions were seen with a group of Hürthle cells against a background of hemorrhage. He was classified as ATA intermediate risk and underwent total thyroidectomy with central neck dissection at another tertiary care facility. His histopathology report revealed a classic papillary thyroid carcinoma, 5.0 cm in diameter, with minimal extra thyroidal extension (right thyroid lobe). In addition, papillary microcarcinoma, Hürthle cell variant (0.5 cm), and follicular adenoma (left thyroid lobe) were reported as well with level VI lymph node micrometastasis. However, no capsular invasion was seen. He received postoperative 5550 MBq (150 mCi) RAI131 for remnant tissue ablation and was started on suppressive thyroid hormone replacement. He has been in follow-up for 3 years with no evidence of residual or recurrent disease.
To the best of our knowledge this is the first case series reported of familial non-medullary carcinoma of the thyroid from Pakistan. Because the number of affected patients was more than two it is highly unlikely that the NMTC was due to sporadic mutations. No specific gene has been associated with heritability; therefore, no genetic testing is available to check for the specific gene. Therefore, clinicians have to rely on a strong family history of this variant of thyroid cancer to diagnose familial cases. In our case series, three brothers were affected; Charkes stated that when three or more family members are affected the probability of this due to sporadic mutations is less than 6 %; thus, we believe that FNMTC in our patients due to sporadic mutations is highly unlikely . Although some researchers argue that familial clustering could be due to environmental exposure and bias due to more aggressive screening in asymptomatic family members, increasing evidence is now accumulating on the hereditability of NMTC. In our study, Patient 1 had a follicular carcinoma in the left and papillary carcinoma in the right lobe, respectively. In addition, Patient 2 had a classic papillary thyroid carcinoma along with papillary microcarcinoma, Hürthle cell variant, and follicular adenoma (left thyroid lobe), suggesting similar genetic mutations in the pathogenesis of FNMTC. As yet, the underlying genetic mutation involved in FNMTC has not been identified, although it has been suggested that FNMTC is a polygenic cancer syndrome as several susceptibility genes and candidate chromosomal loci have been reported [5–7].
All three of our patients had minimal symptoms but advanced disease at presentation. Lymph nodes metastasis was seen in Patients 2 and 3 whereas capsular invasion was present in Patient 3 only. This aggressive picture is supported by a meta-analysis by Wang et al. which showed that FNMTC is more aggressive at presentation with a higher degree of recurrence due to increased multifocality, extrathyroid invasion, bilateral presentation, and lymph node involvement and is associated with less disease-free survival as compared to sporadic NMTC . It is also associated with anticipation, widespread disease at presentation and a worse outcome when compared to the first generation . The best predictors of prognosis are the number of family members affected and metastasis at presentation, both of which increase mortality . However, one study suggested that if treated early, FNMTC does not decrease life expectancy of patients .
Total thyroidectomy was performed for all patients with additional neck dissection for Patients 2 and 3. Furthermore, all three patients were given RAI131. This signifies the role of aggressive treatment in the face of FNMTC. Sippel et al. recommend this approach followed by RAI and thyroid hormone suppression therapy to prevent recurrence and decrease mortality .
As specific gene testing is not available, identification of cases of FNMTC relies on a good family history and detailed pedigree analysis. In cases where clinical data suggest the presence of FNMTC, ultrasound should be used for the screening of close relatives for earlier diagnosis and better outcomes. Since FNMTC is known to be particularly aggressive, patients should be a treated with total thyroidectomy and neck dissection and kept under close follow-up with regular evaluations to detect recurrences.
ATA, American Thyroid Association; FNA, fine-needle aspiration; FNAC, fine-needle aspiration cytology; FNMTC, familial non-medullary thyroid carcinoma; NMTC, non-medullary thyroid carcinoma; PET, positron emission tomography; RAI131, radioactive iodine131; SUV, standardized uptake value; T3, triiodothyronine; T4, thyroxine; TPO, thyroid peroxidase; TSH, thyroid-stimulating hormone
Availability of data and materials
Since this is a case series, no statistical analysis was done and almost all the raw data have been included. However, if any further details regarding our patients are required we will be happy to provide them.
OR conceived the study and helped draft the manuscript. NH and NI were involved in patient care and helped write the case presentation. SF and ZK also helped draft the manuscript and also edited it. SS and SP were involved in providing description of histopathology for the figures and also helped write the description section. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975–2012, National Cancer Institute. http://seer.cancer.gov/csr/1975_2012/. Accessed 6 Mar 2016.
- Nosé V. Familial non-medullary thyroid carcinoma: an update. Endocr Pathol. 2008;19(4):226–40.View ArticlePubMedGoogle Scholar
- Sippel RS, Caron NR, Clark OH. An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up. World J Surg. 2007;31:924–33.View ArticlePubMedGoogle Scholar
- Charkes ND. On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. Thyroid. 2006;16:181–6.View ArticlePubMedGoogle Scholar
- Vriens MR, Suh I, Moses W, Kebebew E. Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. Thyroid. 2009;19:1343–9.View ArticlePubMedGoogle Scholar
- Cao J, et al. Clinicopathological features and prognosis of familial papillary thyroid carcinoma – a large-scale, matched, case–control study. Clin Endocrinol. 2016;84:598–606. doi:10.1111/cen.12859.View ArticleGoogle Scholar
- McDonald TJ, et al. Familial papillary thyroid carcinoma: a retrospective analysis. J Oncol. 2011;2011:948786. doi:10.1155/2011/948786.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang X, et al. Endocrine tumours: familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis. Eur J Endocrinol. 2015;172(6):R253–62.View ArticlePubMedGoogle Scholar
- Capezzone M, Marchisotta S, Cantara S, Busonero G, Brilli L, Pazaitou-Panayiotou K, et al. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. Endocrine Related Cancer. 2008;15(4):1075–81.View ArticlePubMedGoogle Scholar
- Alsanea O, Wada N, Ain K, Wong M, Taylor K, Ituarte P, et al. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery. 2000;128(6):1043–51.View ArticlePubMedGoogle Scholar
- Triponez F, Wong M, Sturgeon C, Caron N, Ginzinger DG, Segal MR, et al. Does familial non-medullary thyroid cancer adversely affect survival? World J Surg. 2006;30(5):787–93.View ArticlePubMedGoogle Scholar